Evogene (NASDAQ:EVGN) Share Price Passes Below Two Hundred Day Moving Average of $0.77

Evogene Ltd. (NASDAQ:EVGN)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.77 and traded as low as $0.63. Evogene shares last traded at $0.64, with a volume of 66,637 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on Evogene in a research note on Thursday. They issued a “sell” rating on the stock.

Evogene Trading Down 5.9 %

The firm’s fifty day moving average price is $0.69 and its 200-day moving average price is $0.77. The company has a market cap of $26.81 million, a price-to-earnings ratio of -1.41 and a beta of 1.40.

Evogene (NASDAQ:EVGN) last posted its earnings results on Thursday, May 23rd. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter. Evogene had a negative net margin of 233.66% and a negative return on equity of 70.96%. The business had revenue of $4.19 million during the quarter.

Institutional Trading of Evogene

A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets grew its stake in Evogene Ltd. (NASDAQ:EVGN) by 30.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 91,400 shares of the biotechnology company’s stock after buying an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned 0.22% of Evogene worth $69,000 at the end of the most recent reporting period. 10.40% of the stock is owned by institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.